WallStreetZenWallStreetZen

NASDAQ: REPL
Replimune Group Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for REPL

Based on 4 analysts offering 12 month price targets for Replimune Group Inc

Min Forecast
$2.00-63.03%
Avg Forecast
$6.75+24.77%
Max Forecast
$14.00+158.78%

Should I buy or sell REPL stock?

Based on 4 analysts offering ratings for Replimune Group Inc.

Buy
Strong Buy
1 analysts 25%
Buy
0 analysts 0%
Hold
3 analysts 75%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although REPL's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates REPL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their REPL stock forecasts and price targets.

REPL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-30
lockedlocked$00.00+00.00%2026-04-13
lockedlocked$00.00+00.00%2026-04-13
lockedlocked$00.00+00.00%2026-02-05

1 of 1

Forecast return on equity

Is REPL forecast to generate an efficient return?

Company
-28%
Industry
89.71%
Market
175.46%
REPL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is REPL forecast to generate an efficient return on assets?

Company
-14%
Industry
26.62%
REPL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

REPL earnings per share forecast

What is REPL's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$2.30
Avg 2 year Forecast
-$1.27
Avg 3 year Forecast
-$0.55

REPL revenue forecast

What is REPL's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$20.7M
Avg 2 year Forecast
$79.5M
Avg 3 year Forecast
$120.8M

REPL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
REPL$5.41$6.75+24.77%Buy
KYTX$7.49$27.00+260.48%Strong Buy
SGMT$7.31$28.75+293.30%Strong Buy
CABA$2.72$15.75+479.04%Strong Buy
IMMX$8.55$21.29+148.96%Strong Buy
View Top Biotech Stocks

Replimune Group Stock Forecast FAQ

Is Replimune Group Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: REPL) stock is to Buy REPL stock.

Out of 4 analysts, 1 (25%) are recommending REPL as a Strong Buy, 0 (0%) are recommending REPL as a Buy, 3 (75%) are recommending REPL as a Hold, 0 (0%) are recommending REPL as a Sell, and 0 (0%) are recommending REPL as a Strong Sell.

If you're new to stock investing, here's how to buy Replimune Group stock.

What is REPL's earnings growth forecast for 2027-2029?

(NASDAQ: REPL) Replimune Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.72%.

Replimune Group's earnings in 2026 is -$313,940,000.On average, 9 Wall Street analysts forecast REPL's earnings for 2027 to be -$193,023,503, with the lowest REPL earnings forecast at -$279,705,276, and the highest REPL earnings forecast at -$69,632,511. On average, 7 Wall Street analysts forecast REPL's earnings for 2028 to be -$106,518,015, with the lowest REPL earnings forecast at -$175,227,129, and the highest REPL earnings forecast at -$34,375,543.

In 2029, REPL is forecast to generate -$46,522,408 in earnings, with the lowest earnings forecast at -$78,975,607 and the highest earnings forecast at -$881,424.

What is REPL's revenue growth forecast for 2027-2029?

(NASDAQ: REPL) Replimune Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.

Replimune Group's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast REPL's revenue for 2027 to be $1,737,077,217, with the lowest REPL revenue forecast at $0, and the highest REPL revenue forecast at $4,750,876,387. On average, 7 Wall Street analysts forecast REPL's revenue for 2028 to be $6,670,366,438, with the lowest REPL revenue forecast at $32,906,503, and the highest REPL revenue forecast at $13,301,110,760.

In 2029, REPL is forecast to generate $10,141,414,900 in revenue, with the lowest revenue forecast at $551,183,927 and the highest revenue forecast at $19,079,895,644.

What is REPL's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: REPL) forecast ROA is -14%, which is lower than the forecast US Biotechnology industry average of 26.62%.

What is REPL's Price Target?

According to 4 Wall Street analysts that have issued a 1 year REPL price target, the average REPL price target is $6.75, with the highest REPL stock price forecast at $14.00 and the lowest REPL stock price forecast at $2.00.

On average, Wall Street analysts predict that Replimune Group's share price could reach $6.75 by Jun 30, 2027. The average Replimune Group stock price prediction forecasts a potential upside of 24.77% from the current REPL share price of $5.41.

What is REPL's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: REPL) Replimune Group's current Earnings Per Share (EPS) is -$3.38. On average, analysts forecast that REPL's EPS will be -$2.30 for 2027, with the lowest EPS forecast at -$3.33, and the highest EPS forecast at -$0.83. On average, analysts forecast that REPL's EPS will be -$1.27 for 2028, with the lowest EPS forecast at -$2.09, and the highest EPS forecast at -$0.41. In 2029, REPL's EPS is forecast to hit -$0.55 (min: -$0.94, max: -$0.01).

What is REPL's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: REPL) forecast ROE is -28%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.